
DLA Piper advised Heron Therapeutics, a commercial-stage biotechnology company, on its definitive asset purchase agreement with CorMedix Therapeutics.
Under the agreement, CorMedix has agreed acquire substantially all of Heron’s assets, and assume certain liabilities, for US$145 million in cash, 14,583,333 shares of CorMedix common stock (valued at US$77.6 million based on CorMedix’s November 6, 2026 closing price), up to US$55 million in contingent earn-out payments, and royalties on net sales of certain Heron products.
The DLA Piper deal team was led by Partners Andrew Gilbert, Jeffrey Scharfstein, Emilio Ragosa, Carina Meleca and Gina Lee.
The team also included Associates Lisa Liu, Thais Lopez, Brian Sunberg and Destiny Harrison, with additional support from Partners Lauren Murdza, Michelle Lara, W. Kurtis Weaver, Jeffrey Aronson, Georgia Jolink, Paolo Morante, Richard Marks, Jennifer Kashatus, Preeya Pinto, Christopher Mikson, and Of Counsel Bryna Shmerling.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record

